NCT02408913View on ClinicalTrials.gov

VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

March 26, 2015

Primary Completion Date

April 6, 2017

Study Completion Date

April 6, 2017

Conditions

Healthy Adult Immune Responses to Vaccine

Interventions

BIOLOGICAL

VRC-EBOMVA079-00-VP (MVA-EbolaZ)

Ebola Modified Vaccinia Virus Ankara Vaccine

BIOLOGICAL

VRC-EBOADC069-00-VP (cAd3-EBO)

Ebola Chimpanzee Adenovirus Vector Vaccine

Trial Locations (3)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

30030

Hope Clinic - Emory Vaccine Ctr, Decatur

21201-1595

University of Maryland, Baltimore, Baltimore

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02408913 - VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults | Biotech Hunter | Biotech Hunter